A consortium involving two African institutions has received £3.1 million (US$5m) from the UK's Wellcome Trust to fast-track trials of a candidate Ebola vaccine in 200 healthy volunteers in Kenya and Gabon.
The trials are part of a series also taking place in Germany and Switzerland to test the safety of rVSV-EOV, a vaccine donated by the Public Health Agency of Canada. A gene from the outer protein of the animal pathogen, vesicular stomatitis virus, has been replaced with a gene of an Ebola strain to make the vaccine.
The World Health Organization will oversee the trials, which will be “swiftly” conducted by a team that includes researchers from Gabon’s Lambarene Medical Research Centre and the Kenya Medical Research Institute-Wellcome Trust research programme.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.